PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18294936-8 2009 Since buprenorphine is metabolized through cytochrome P450 3A4, we genotyped six genetic polymorphisms previously described in poor metabolizers but could not confirm these pharmacogenetic bases in this case. Buprenorphine 6-19 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 43-62 28097004-13 2016 This can be mainly explained by an enhancement of CYP3A-mediated first-pass metabolism, which sublingual buprenorphine only partially bypasses. Buprenorphine 105-118 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 50-55 21515002-4 2011 Buprenorphine N-dealkylation to norbuprenorphine is primarily performed by CYP3A. Buprenorphine 0-13 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 75-80 22845044-2 2012 This study evaluated the effect of ketoconazole, a CYP3A4 inhibitor, on the metabolism of buprenorphine following the administration of a buprenorphine transdermal system 10 mug/hour (BTDS 10). Buprenorphine 90-103 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 51-57 22148986-7 2012 CYP3A4 inactivates methadone, meperidine, and buprenorphine. Buprenorphine 46-59 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 20829393-4 2010 In HepG2 cells, buprenorphine significantly increased human PXR-mediated CYP2B6 and CYP3A4 reporter activities. Buprenorphine 16-29 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 84-90 20829393-6 2010 Real-time reverse transcription-polymerase chain reaction analysis revealed that buprenorphine strongly induced CYP3A4 expression in both PXR- and CAR-transfected HepG2 cells. Buprenorphine 81-94 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 112-118 20829393-8 2010 Further studies indicated that buprenorphine could neither translocate human CAR to the nucleus nor activate CYP2B6/CYP3A4 reporter activities in transfected HPHs. Buprenorphine 31-44 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 116-122 16507617-13 2006 QT interval increases were observed with buprenorphine/naloxone in combination with either delavirdine or ritonavir, which inhibit CYP3A4. Buprenorphine 41-54 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 131-137 17598095-8 2007 Both amitriptyline and buprenorphine were strong, reversible inhibitors of CYP3A4. Buprenorphine 23-36 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 75-81 34679189-10 2022 PBPK modeling and simulation demonstrated that variability in biliary clearance, sublingual absorption, and CYP3A4 abundance are likely important drivers of buprenorphine PK variability in neonates. Buprenorphine 157-170 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 108-114 15966752-13 2005 Although there is limited evidence in the literature to date, drugs that are known to inhibit or induce CYP3A4 have the potential to diminish or enhance buprenorphine N-dealkylation. Buprenorphine 153-166 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 104-110 12756210-4 2003 Buprenorphine exhibited potent, competitive inhibition of CYP2D6 (Ki 10 +/- 2 microM and 1.8 +/- 0.2 microM) and CYP3A4 (Ki 40 +/- 1.6 microM and 19 +/- 1.2 microM) in microsomes from human liver and cDNA-expressing lymphoblasts, respectively. Buprenorphine 0-13 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 113-119 12756210-6 2003 Furthermore, buprenorphine was shown to be a substrate of CYP2D6 (Km = 600 microM; Vmax = 0.40 nmol/min/mg protein) and CYP3A4 (Km = 36 microM; Vmax = 0.19 nmol/min/mg protein). Buprenorphine 13-26 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 120-126 12756210-7 2003 The present in vitro study suggests that buprenorphine and its major metabolite norbuprenorphine are inhibitors of CYP2D6 and CYP3A4; however, at therapeutic concentrations they are not predicted to cause potentially clinically important drug interactions with other drugs metabolized by major hepatic P450s. Buprenorphine 41-54 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 126-132 10873929-6 2000 Buprenorphine inhibited the formation of CYP3A4-mediated pathways of 3-hydroxyflunitrazepam and omeprazole sulfone formation (K(i) 118 and 16 microM) in human liver microsomes. Buprenorphine 0-13 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 41-47 10873929-8 2000 Projected in vivo inhibition of CYP3A4-mediated metabolism of flunitrazepam by buprenorphine is 0. Buprenorphine 79-92 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 32-38 10755464-3 2000 Since buprenorphine and many benzodiazepines are CYP3A substrates, the effect of buprenorphine on CYP3A activity was examined in order to assess the likelihood of a pharmacokinetic interaction. Buprenorphine 81-94 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 98-103 10755464-5 2000 Buprenorphine was found to be a weak inhibitor of CYP3A with a 50% decrease in enzyme activity occurring at a concentration of 118 microM (IC50) in human liver microsomes. Buprenorphine 0-13 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 50-55 15501692-7 2004 Buprenorphine, too, is metabolised by CYP3A4, and may undergo the same interactions as methadone. Buprenorphine 0-13 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 38-44 12033517-3 2002 Buprenorphine strongly inhibited the CYP3A4- and CYP2D6-catalyzed reactions with Ki values of 14.7 microM and 21.4 microM, respectively. Buprenorphine 0-13 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 37-43 9698298-0 1998 Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Buprenorphine 6-19 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 51-70 9565774-1 1998 Methadone and buprenorphine, widely used in the treatment of opioid abuse, are metabolized by cytochrome P450 3A4, while fluoxetine and fluvoxamine, both selective serotonin reuptake inhibitors, are known to be P450 2D6 and 3A4 inhibitors in vitro. Buprenorphine 14-27 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 94-113 9180349-0 1997 Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Buprenorphine 56-69 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 15-34 32585880-5 2020 Moreover, the drug-drug interaction (DDI) potential of buprenorphine with CYP3A4 and P-glycoprotein perpetrator drugs should be elucidated. Buprenorphine 55-68 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 74-80 34520028-14 2021 Co-prescription of medications known to interact with cytochrome P450 3A4 was associated with nondetection of BPN (p < 0.05). Buprenorphine 110-113 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 54-73 34520028-17 2021 Failure to detect BPN does not betoken nonadherence to treatment and is associated with co-prescription of drugs interacting with cytochrome P450 3A4. Buprenorphine 18-21 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 130-149 33154520-9 2021 Variations of the pharmacokinetic gene for CYP3A4 showed that the ultrarapid metabolizer phenotype required higher doses of buprenorphine. Buprenorphine 124-137 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 43-49 35304767-12 2022 Median urine concentrations of buprenorphine were highest at 2 hours and were higher in participants receiving CYP3A4 inhibitors. Buprenorphine 31-44 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 111-117 33750027-2 2021 Buprenorphine undergoes extensive cytochrome P450 (CYP) 3A4 metabolism, leading to potential drug-drug interactions (DDIs) as reported for sublingual buprenorphine. Buprenorphine 0-13 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 34-59 33750027-2 2021 Buprenorphine undergoes extensive cytochrome P450 (CYP) 3A4 metabolism, leading to potential drug-drug interactions (DDIs) as reported for sublingual buprenorphine. Buprenorphine 150-163 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 34-59 33750027-9 2021 Daily coadministration of strong CYP3A4 inhibitors with BUP-XR predicted mild increases in buprenorphine exposures (AUC, 33%-44%; Cmax , 17-28%). Buprenorphine 91-104 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 33-39 33750027-10 2021 Daily coadministration of a strong CYP3A4 inducer was also associated with mild decreases in buprenorphine AUC (28%) and Cmax (22%). Buprenorphine 93-106 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 35-41 33750027-11 2021 In addition, the model predicted minimal increases in buprenorphine AUC (8%-11%) under clinical conditions of 2 weeks" treatment with CYP3A4 inhibitors administered after initiation of BUP-XR. Buprenorphine 54-67 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 134-140 30167757-11 2018 CONCLUSIONS: Voriconazole greatly increases exposure to oral buprenorphine, mainly by inhibiting intestinal and liver CYP3A4. Buprenorphine 61-74 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 118-124 30167757-13 2018 Although oral buprenorphine is not commonly used, this interaction may become relevant in patients receiving sublingual buprenorphine together with voriconazole or other CYP3A4 or transporter inhibitors. Buprenorphine 14-27 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 170-176 29102550-0 2018 A Physiologically Based Pharmacokinetic Modeling Approach to Predict Drug-Drug Interactions of Buprenorphine After Subcutaneous Administration of CAM2038 With Perpetrators of CYP3A4. Buprenorphine 95-108 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 175-181 29102550-4 2018 The strong CYP3A4 inhibitor ketoconazole was predicted to increase the buprenorphine exposure by 35% for the Q1W formulation and 34% for Q4W formulation, respectively. Buprenorphine 71-84 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 11-17 29102550-5 2018 Also, the strong CYP3A4 inducer rifampin was predicted to decrease the buprenorphine exposure by 26% for both the Q1W and Q4W formulations. Buprenorphine 71-84 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 17-23 29450233-9 2017 Pharmacogenetic testing revealed that the patient exhibited a cytochrome P450 3A4 ultrarapid metabolizer phenotype, which necessitated a higher than recommended daily dose of buprenorphine (32 mg) for adequate OUD management. Buprenorphine 175-188 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 62-81